Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 8/20 | 0.68 |
| ▸ | DRD3 | P35462 | 8/20 | 0.61 |
| ▸ | DRD2 | P14416 | 6/20 | 0.61 |
| ▸ | NAMPT | P43490 | 1/20 | 0.56 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.52 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.52 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL763421 | 0.83 | KCNA5 (0.70) | KCNA5DRD3DRD2NAMPT | |
| SCHEMBL16256936 | 0.83 | KCNA5 (0.59) | KCNA5DRD3DRD2PDK1PDK2 | |
| SCHEMBL16358258 | 0.82 | DRD3 (0.61) | KCNA5DRD3DRD2NAMPTMEN1 | |
| SCHEMBL19145557 | 0.82 | DRD3 (0.61) | KCNA5DRD3DRD2NAMPT | |
| SCHEMBL2222735 | 0.82 | DRD3 (0.58) | KCNA5DRD3DRD2NAMPT | |
| SCHEMBL23775636 | 0.82 | KCNA5 (0.62) | KCNA5DRD3DRD2PDK1PDK2 | |
| SCHEMBL8408009 | 0.82 | KCNA5 (0.56) | KCNA5DRD3DRD2PDK1PDK2 | |
| SCHEMBL22221560 | 0.82 | KCNA5 (0.58) | KCNA5DRD2PDK1PDK2PDK3 | |
| SCHEMBL8386395 | 0.80 | KCNA5 (0.57) | KCNA5DRD3DRD2PDK1PDK2 | |
| SCHEMBL17886738 | 0.80 | HPGD (0.65) | KCNA5DRD3DRD2NAMPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2822656-B1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | CANCER RES INST ROYAL (GB) | 2016-10-19 | — | — | EP | disclosed |
| US-9193689-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-11-24 | — | — | US | disclosed |
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | TNKS, TNKS2, PARP11 | KCNA5 3986/4885DRD3 3299/4885DRD2 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.